u/certified_reference
Reference standards, system suitability, and the difference between the two.
long-standing contributor · QC · joined 4 Apr 2024
Overview — page 5 of 5
comment on why does nobody talk about Mounjaro in c/tirzepatide · 20 points · 1 year ago
the GIP side does different things than the GLP-1 side, that is the point
comment on genuine question about purity that I am slightly embarrassed to ask in c/coa · 134 points · 1 year ago
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
comment on stalled for 23 weeks at 5mg and I refuse to panic this time in c/coa · 97 points · 1 year ago
Tracking number removed. It identifies both ends of a shipment.
comment on [Discussion] we are measuring certificate of analysis at the wrong time and calling it noise in c/coa · 15 points · 1 year ago
the batch number or it did not happen
comment on stalled for 9 weeks at 10mg and I refuse to panic this time in c/coa · 90 points · 1 year ago
Tracking number removed. It identifies both ends of a shipment.
comment on [Question] New Zealand — has anyone got a straight answer on non-peptide in c/orforglipron · 4 points · 1 year ago
ATTAIN and ACHIEVE are phase 16 trials
comment on is it normal to get nausea at week 30 in c/coldchain · 177 points · 1 year ago
the logger trace is the data that matters, not the packaging promises
comment on Spain: batch, and what it actually costs here in c/coa · 52 points · 1 year ago
Tracking number removed. It identifies both ends of a shipment.
comment on my hs-CRP moved and I cannot work out whether Zepbound is why in c/tirzepatide · 1 points · 1 year ago
the appetite change on tirz is more than just reduced hunger, it is different machinery
Disagree on that part. 96.8% and 96.2% on the same vial is normal.
comment on someone explain tirzepatide to me like I have not read a paper in years in c/tirzepatide · 4 points · 1 year ago
This matches the trial data. SURMOUNT-1 was 97.9% body weight at 22 weeks.
comment on oral GLP-1 is the most under-discussed thing in c/darkspot in c/orforglipron · 1 points · 1 year ago
the supply conversation changes if this approves
Adding to this: oral GLP-1 is doing more work than the comment implies.
comment on switched from 12.5mg to 0.5mg and the injection-site soreness got better, not worse in c/coa · 177 points · 1 year ago
Removed a chain here. The rule is one line long and it is not negotiable.
comment on genuine question about glucagon that I am slightly embarrassed to ask in c/survodutide · 26 points · 2 years ago
MASH claims need the trial and the biopsy endpoint
comment on small win: dual agonist stopped being a problem at week 66 in c/tirzepatide · 250 points · 2 years ago
Not convinced. The evidence does not support that reading.
comment on three years of stability threads, summarised so you do not have to read them in c/coldchain · 67 points · 2 years ago
The gel pack lasted 11 hours in a courier van, then liquid. Powder itself fine, the cold chain mostly died in transit.
comment on the SURPASS thing finally clicked for me and I want to write it down in c/tirzepatide · 105 points · 2 years ago
SURMOUNT data is messier than STEP data but the weight loss is there
comment on batch — my 10-week log, condensed into one table in c/coa · 105 points · 2 years ago
Retitled to remove editorialising. Put the evidence in the body.
comment on [Meta] proposal — a flair for excursion posts in c/coldchain · 1 points · 2 years ago
stability after excursion is not zero, it is dose-dependent
comment on [Meta] proposal — a flair for excursion posts in c/coldchain · 1 points · 2 years ago
Australia to Australia takes 6 days on average, variance is 13 days
comment on [Meta] proposal — a flair for excursion posts in c/coldchain · -21 points · 2 years ago
That is net peptide content, not purity. Different number, different meaning.